Kornimate/medical-research-clean huggingface dataset:
development and validation of a novel functional eye-tracking software application for cancer-related cognitive impairment (crci)

Conditions: Cancer-related Cognitive Impairment

Summary: this study aims to develop and validate a sensitive and non-invasive eye-tracking software application.

this study will obtain participant responses to brief cognitive tests designed to evaluate several key functions known to be affected by the cancer-related cognitive impairment (crci) and non-invasive eye movement measurements in response to visually presented stimuli during specifically designed eye-tracking tests. the study data will be used to develop machine learning algorithms and validate a software application intended to track the progressive component of the cancer-related cognitive impairment (crci) and associated cognitive changes.

Eligibility criteria:
inclusion criteria: * for all participants: 1. able to provide informed consent. 2. visual acuity sufficient to be able to read the consent form with corrective lenses. 3. over 18 years of age. 4. english- or french-speaking. * for patients only: 1. initial diagnosis of breast cancer stage i-iiia and scheduled chemotherapy 2. first-time cancer diagnosis. 3. ecog performance \< 2 4. receiving curative intent chemotherapy: either adriamycin/cyclophosphamide for 4 cycles followed by weekly taxol for 12 cycles or taxotere/cyclophosphamide for 4 cycles exclusion criteria: * for all participants: 1. evidence or medical history of neurological/psychiatric issues known to affect movements and oculomotor control. 2. presence of comorbid neurological conditions to avoid eye movement anomaly confounds (strabismus, cranial nerve palsy, stroke-causing hemianopsia). 3. diagnosis of macular edema or other pre-existing ocular conditions that would prevent participants from performing the eye movement assessments. 4. previous history of cancer or chemotherapy 5. distant metastases 6. recent (less than three months from enrollment) start of, change of dose, or irregular use of, new prescription drugs known to influence ocular motor visual function, such as benzodiazepines, antipsychotics and anticonvulsants. occasional use of benzodiazepines for medical procedures is permitted, at the investigator's discretion, but should not occur within a short time period prior to or during an eye movement assessment. 7. diagnosis of a substance abuse disorder. 8. recreational drug use (e.g., alcohol, marijuana) is a potential exclusion criterion that will be determined on an individual basis as per the discretion of the research team. all recreational drug use will be documented.

Keywords: cancer-related cognitive impairment (crci) eye movement biomarkers eye-tracking
effect of januvia on ghrelin and other gut hormones in patients with diabetes

Conditions: Type 2 Diabetes

Summary: the purpose of this study is to see the effect of januvia on ghrelin levels in patients with diabetes.


Eligibility criteria:
inclusion criteria: * patients with type 2 diabetes exclusion criteria: * renal failure * pregnancy
effect of skeletally anchored reversed powerscope appliance in orthodontic treatment of patients with class iii malocclusion

Conditions: Effect of PowerScope Appliance in Treatment of Patients With Class 3 Malocclusion

Summary: the powerscope appliance is found to be efficient for the treatment of class ii malocclusion. accordingly, it appears valuable to investigate the efficiency of skeletally anchored powerscope in the treatment of class iii malocclusion

the powerscope is the latest innovation in the treatment of class ii malocclusion which is a direct derivative of the herbst type ii appliance. dr. andy hayes worked in conjunction with american orthodontics to develop powerscope in 2016. this appliance supports intermaxillary wire-to-wire installation via a nut and hexagonal screw. a ball and socket joint is used to maximize lateral movement while improving patient comfort. the appliance is made up of a telescopic mechanism made up of an inner shaft/push rod, middle and outer tubing, and a spacer between the middle and outer tubing. a nickel-titanium (niti) spring provides a constant 260 g force. according to the present knowledge no studies regarding treatment outcomes of comprehensive fixed appliance treatment combined with the powerscope in class ιii patients have been reported. the introduction of temporary anchorage devices (tads) has made it possible to achieve absolute anchorage control in daily clinical orthodontic practice when used in conjunction with fixed functional appliances. however, it appears that there is no evidence in the literature supporting the clinical effectiveness of miniscrew- anchored fixed functional appliances for the treatment of class iii malocclusion. according to the current available literature, the powerscope appliance is found to be efficient for the treatment of class ii malocclusion. accordingly, it appears valuable to investigate the efficiency of skeletally anchored powerscope in the treatment of class iii malocclusion.

Eligibility criteria:
inclusion criteria : 1. mild to moderate class iii malocclusion adolescent patients with anb (-3 - 0). 2. all permanent teeth are erupted (3rd molar not included). 3. an age of patients range from 14 to 18 years. 4. good oral and general health. 5. no systemic disease or regular medication that could interfere and/or affect orthodontic teeth movement. 6. no previous orthodontic treatment. exclusion criteria: 1. orthodontic cases with severe crowding of upper and lower anterior segment that require extraction treatment approach. 2. patients with a blocked-out tooth that will not allow for placement of the bracket at the initial bonding appointment.
a study to evaluate the safety and efficacy of an investigational drug in hiv infected patients (0518-004)(completed)

Conditions: HIV Infections; Acquired Immunodeficiency Syndrome

Summary: this is a study that will investigate the safety and efficacy of an investigational drug in human immunodeficiency virus (hiv) infected patients.

participants who completed 48 weeks of the original 48-week double-blind study were invited to continue in two extensions: mk0518-004-10 (nct00100048), which extended the study to 144 weeks, and mk0518-004-20 (nct00100048), which extended the study to 240 weeks. participants who had been randomized to mk0518 in the base study continued at 400 mg mk0518 twice daily. participants randomized to efavirenz in the base study continued to receive efavirenz at the dosage given in the base study. the doses of open label tenofovir and lamivudine continued unchanged.

Eligibility criteria:
inclusion criteria: * patient must be hiv positive who must have received less than 7 days total of any antiretroviral therapy (hiv related therapy) extension studies: * first extension: patient completed the 48-week base study * second extension: patient completed the first 144-week extension study exclusion criteria: * less than 18 years of age * individuals who currently do not test positive for hiv
diagnosis of bone metabolism in patients with inexplicable lower back pain

Conditions: Lower Back Pain Chronic

Summary: the main goal of this study is to determine if static or dynamic \[18f\]naf pet/ct (positron emitting tomography) can identify the source of lower backpain in at least 20% of the patients experiencing lower backpain, yet could not be diagnosed from mri or ct scans.

patients with chronic lower backpain are routinely scanned with mr and/or ct to diagnos the source of pain. larger studies have reported that approximately 20% of patients are given a certain diagnosis from the scans and in the majority of cases the source of the pain is not determined. the use of \[18f\]naf pet/ct to map bone perfusion and metabolism is a routine clinical scan that can potentially identify the source of lower backpain in mri and ct negative patients. hypothesis: that \[18f\]naf pet/ct bone metabolism and bone perfusion images would contain information that allow the correct diagnosis in at least 20% of patients where mri and ct images did not reveal pathology.

Eligibility criteria:
inclusion criteria: * over 18 years * chronic lower back pain with no concrete diagnosis after mri and/or ct * under the the care of rigshospitalets centre for rheumatology and spine disease exclusion criteria: * previous operation in the lower back area * known inflammatory related illness or progressive rheumatism

Keywords: naf pet bone metabolism bone perfusion
pedal arch revascularization in patients with chronic limb threatening ischemia

Conditions: Critical Ischemia of Foot

Summary: chronic limb threatening ischemia (clti) is a major cause of morbidity and mortality worldwide and is characterized by multilevel disease, often involving the tibiopedal vessels . clti is an undesirable clinical consequence of peripheral arterial disease (pad) . it affected ∼8 million people in the usa and affects 12-20% of american people aged more than 65 years. within 1 year of diagnosis, 25% of those patients progress to a major amputation and the other 25% die due to co-morbid conditions

revascularization is the cornerstone of chronic limb threatening ischemia (clti) treatment for lower limb preservation . endovascular revascularization is the favored approach in many centers because of its lower morbidity and mortality than open surgery . in a subset of patients with chronic limb threatening ischemia, particularly in longstanding type 1 diabetic patients, a predominance of disease involving the pedal vessels can exist with relative sparing of the tibial vessels .the pedal arch describes the connection between the anterior and posterior circulation in the foot, this typically runs from the lateral plantar artery into the dorsalis pedis and represents the final arcade of outflow for the lower extremity vasculature . secondary or "deep" pedal plantar loops connecting the medial and lateral tarsal arteries to the medial and lateral plantar arteries can also exist . a strong understanding of the pedal arch anatomy and its multiple connections is important for the physician performing not only pedal arch interventions, but tibial interventions as well . familiarity with the arch anatomy increases procedural success rates in tibial intervention, as it gives the operator another collateral pathway to approach the target occlusion in a retrograde fashion . an intact pedal arch has been associated with improved wound healing, as well as a higher patency rate for bypass grafting and percutaneous interventions for inflow disease . an angio some-directed revascularization strategy, however, has clearly been shown to improve wound healing and limb salvage rates in both surgical and endovascular series . pedal arch intervention should therefore be considered in patients with advanced tissue loss, with a goal of restoring inline flow to the corresponding angiosomes, this could mean the difference between a major and minor amputation, as the options for these patients are limited and major amputation rates are high .

Eligibility criteria:
inclusion criteria: all patients with chronic limb threatening ischemia present with one or more of the following: * rest pain (rutherford category 4) * minor tissue loss (rutherford category 5) admitted to the department of vascular surgery for endovascular intervention with provided written informed consent. exclusion criteria: * patients presented with proved vasculitis. * patients with chronic liver disease if there is prolonged pt. * patients with heart failure if the patient is orthopneic and cannot lay on table for long time). * patients with impaired renal function.
comparison of electroacupuncture and thread embedded acupuncture with dietary intervention in obese patients

Conditions: Obesity

Summary: the purpose of this study is to compare the effectiveness between electroacupuncture treatment with dietary intervention and thread embedded acupuncture with dietary intervention in reducing body weight, waist circumference, and leptin level in obese patients.

the purpose of this study is to describe reducement in body weight, waist circumference, and leptin level in obese patients with dietary intervention and electroacupuncture or dietary intervention with thread embedded acupuncture. it is also to analyze mean differences of body weight, waist circumference, and leptin level in obese patients between the two interventions. the results of the study expected to be used as an operating standard procedure for obese patients.

Eligibility criteria:
inclusion criteria: * age 18 - 60 years * obese with body mass index (bmi) 25 - 35 kg/m\^2 * waist circumference male \> 90 cm and female \> 80 cm * willing to participate in the study by signing an informed consent * willing to follow the study process until it is finished exclusion criteria: * pregnancy * post partum \< 6 months * diabetes (blood glucose poct (point of care testing) \>= 200 mg/dl) * hypertension (blood pressure \>= 140/90 mmhg) * fever \> 38\^c * has a history of contraindication for electroacupuncture such as history of heart diseases, pace maker, arrhythmia * has a history of contraindication for thread embedded acupuncture such as allergy of pdo (polydioxanone), blood clotting disorder, consumption of anticoagulant drugs, local infection or wound on embedded site * has a history of weight loss drugs consumption (such as orlistat, phentermine, diethylpropion) or slimming supplements (green tea, jati belanda/guazuma ulmifolia) for the last 25 hours. * history of liver disease, kidney disease * has had acupuncture therapy for obesity in the last six months

Keywords: electroacupuncture thread embedded acupuncture obese dietary intervention
perioperative application of omega-3 polyunsaturated fatty acids in gastric cancer patients

Conditions: Gastric Cancer

Summary: to evaluate immunomodulatory effects of perioperative application of omega-3 polyunsaturated fatty acids in gastric cancer surgery, the effects of postoperative recovery, the improvement of nutritional status, incidence rate of related complications, and whether it can reduce the average postoperative hospitalization days.

methods: choose from 6 to 2013-2013-12 gastric cancer patients, according to inclusion criterias to choose the objects of study from the gastric cancer patients coming to our hospital 2013-06 to 2013-12 .the included patients will be randomly divided into two groups a and b, two groups of patients 4 days before operation begin to give parenteral nutrition: a: the control group of normal intravenous nutrition. b: the trial group,add omega-3 polyunsaturated fatty acids 0.2 g/kg to parenteral nutrition, no use on the day of surgery, postoperative 2 days continue to add omega-3 polyunsaturated fatty acids 0.2 g/kg. detect and compare crp、tnf-α、il-1、il-4、ll-6、 il-8、ll-10 levels of two groups in days before parenteral nutrition and applicating 3rd day and postoperative 1st, 3rd, 5th,and detect liver function in preoperative and postoperative 2nd,5th,7th day. record postoperative anal exhaust time, postoperative complications, postoperative hospital days, preoperative and postoperative body weight.results: trail group patients compared with the control group,omega-3 polyunsaturated fatty acids can reduce early postoperative inflammatory cytokines release, reduce the postoperative fever time, reduce the incidence of systemic inflammatory response syndrome, promote the recovery of gastrointestinal function, improve the nutritional state of patients, reduce infection and related complications after the surgery and reduce postoperative hospitalization days. conclusions: perioperative application of omega 3 pufa can reduce the release of inflammatory cytokines, regulating cell and humoral immunity, reduce the postoperative fever time, reduce the local inflammation medium that inhibit the gastrointestinal peristalsis, promote the recovery of gastrointestinal function, improve the nutritional state of patients, thereby reducing the occurrence of postoperative infection and related complications, reduce postoperative hospitalization days.

Eligibility criteria:
inclusion criteria: * patients coming to firstjilinu diagnosed gastric cancer by endoscopy and pathology. * no preoperative treatment, the gastric cancer radical surgery in our hospital is the first treatment. * nutrition screening score (nrs 3 or higher). * albumin and (or) immune enhancer were not used within two weeks before operation . * no blood system diseases. exclusion criteria: * being in the acute phase of inflammation before operation and emergency surgery. * patients combined metabolic diseases such as diabetes, hyperthyroidism, immune system disease or taking immunosuppressants; * combined hepatic insufficiency. * spleen resected in operation

Keywords: omega-3 gastric cancer perioperation
medium-term results of the lps™ system for segmental resection of the distal femur, a multicenter retrospective study (resif)

Conditions: Prosthesis Failure

Summary: the reconstruction of the distal femur using modular systems has become increasingly popular over the years, surpassing primary arthrodesis or amputation. despite the significant advantages of using megaprostheses, complications are not uncommon. although the limb preservation system™ (lps™, depuy synthes; warsaw, usa) is one of the most widely used megaprostheses in the french market, there is currently no national evaluation of this system, and only two studies have been conducted worldwide. the aim of our study is to present the mid-term survival rates of the lps™ implant in order to answer three main questions: 1. what are the overall outcomes of the lps™ system in distal femur replacement? 2. what factors are associated with a reduced survival rate of the implant? 3. what is the cumulative risk of complications according to henderson's classification? the secondary objective is to analyze the occurrence of specific failures, providing insights for potential improvements in the design and use of the lps™ implant.


Eligibility criteria:
inclusion criteria: - patients who underwent distal femoral reconstruction using the lps system. exclusion criteria: * lost to follow-up before 3 months. * associated tibial reconstruction using the lps system. * total femoral reconstruction using the lps system.

Keywords: megaprosthesis knee replacement
effect of an alumina free device surface on bmd in patients implanted with an sl-plus™ femoral stem for tha

Conditions: Hip Osteoarthritis

Summary: alumina particles from the grit blasting of ti-alloy stems for hip arthroplasty are suspected to contribute to aseptic loosening. an alumina-reduced stem surface was hypothesized to improve osseointegration and show comparable short-term outcomes to those of a standard stem.


Eligibility criteria:
inclusion criteria: * patients aged 18 years and older undergoing primary tha for primary or secondary osteoarthritis will be enrolled. exclusion criteria: * exclusion criteria were ongoing therapy with cortisone or medications influencing bone metabolism.
efficacy and safety of oral febuxostat in participants with gout

Conditions: Gout

Summary: the purpose of this study is to compare the efficacy and safety of febuxostat, once daily (qd), to allopurinol in subjects with hyperuricemia and gout.

renal impairment is common in subjects with gout, with the prevalence ranging from 50% to 70%. this population represents an unmet medical need as uricosuric drugs are contraindicated in these patients, and the only available treatment, allopurinol, may have to be dose reduced to avoid overt side effects. febuxostat (tmx-67) is a non-purine selective xanthine oxidase inhibitor being developed as an orally administered agent for management of hyperuricemia in patients with gout. treatment duration will be 6 months.

Eligibility criteria:
inclusion criteria: * has one or more of the american rheumatism association criteria for the diagnosis of gout. * females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from screening throughout the duration of the study. * must have a serum urate level greater than or equal to 8.0 milligram per deciliter (mg/dl). exclusion criteria: * have a severe, unstable, or life threatening medical condition that would likely prevent them from completing this study. * has a known body reaction to febuxostat, allopurinol, naproxen, any other non-steroidal anti-inflammatory drug (nsaid), aspirin, lansoprazole, colchicine, or any components in their formulation. * history of xanthinuria. * alcohol consumption greater than 14/week. * history of significant concomitant illness. * active liver or peptic ulcer disease. * has rheumatoid arthritis requiring treatment. * has estimated creatinine clearance less than 30 milliliter per minute (ml/min) calculated using the cockcroft-gault formula corrected for ideal body weight. * requires therapy with any other urate-lowering drug other than the study drug; long-term use of nsaids and cox-2 inhibitors; salicylates; thiazide diuretics; losartan; azathioprine; mercaptopurine; theophylline; intravenous (iv) colchicine; cyclosporine; cyclophosphamide; pyrazinamide; sulfamethoxazole;trimethoprim.

Keywords: tophi hyperuricemia uric acid drug therapy
radioimmunoimaging of al amyloidosis

Conditions: AL Amyloidosis

Summary: the purpose of the study is to determine the capability of a radiolabeled amyloid-reactive monoclonal antibody to document the presence and distribution of amyloid deposits by pet/ct imaging in patients with al amyloidosis.

to be eligible for this study, patients must have a confirmed diagnosis of al amyloidosis without significant cardiac (new york heart association class iv) disease and not be on kidney dialysis. additionally, after testing, their blood must not contain antibodies to mouse proteins. the study requires an intravenous infusion, over 10 minutes, of the radiolabeled antibody, followed 48 hours later by a pet/ct scan. a repeat scan is done 5 or 7 days after infusion of the antibody. a 5 ml blood specimen needs to be furnished 4 and 8 weeks after the antibody infusion.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of al amyloidosis exclusion criteria: * new york heart association class iv * patient on renal dialysis * serum antibodies to mouse protein

Keywords: radioimmunoimaging al amyloidosis pet/ct